Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBITDA (2016 - 2025)

Avalo Therapeutics' EBITDA history spans 12 years, with the latest figure at -$13.7 million for Q4 2025.

  • For Q4 2025, EBITDA rose 61.25% year-over-year to -$13.7 million; the TTM value through Dec 2025 reached -$78.2 million, down 122.58%, while the annual FY2025 figure was -$78.2 million, 122.58% down from the prior year.
  • EBITDA reached -$13.7 million in Q4 2025 per AVTX's latest filing, up from -$30.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $98.5 million in Q2 2024 to a low of -$121.3 million in Q1 2024.
  • Average EBITDA over 5 years is -$13.4 million, with a median of -$13.4 million recorded in 2025.
  • The largest YoY upside for EBITDA was 1301.79% in 2024 against a maximum downside of 1118.38% in 2024.
  • A 5-year view of EBITDA shows it stood at -$18.0 million in 2021, then soared by 50.7% to -$8.9 million in 2022, then grew by 13.52% to -$7.7 million in 2023, then crashed by 361.47% to -$35.3 million in 2024, then surged by 61.25% to -$13.7 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's EBITDA are -$13.7 million (Q4 2025), -$30.6 million (Q3 2025), and -$20.8 million (Q2 2025).